에이비온

203400KOSDAQ자연과학 및 공학 연구개발업

51.0 / 100

Reference Date: 2026-04-13

Financial Score18.0 / 40

News Sentiment20.0 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but Revenue is on a declining trend. Plunged 25.6% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

ABION is a KOSDAQ-listed biopharmaceutical company specializing in the development of anti-cancer drugs and candidates based on companion diagnostics. Key pipelines include Vabametkib for non-small cell lung cancer, ABN101 (an interferon-beta-based antiviral), and ABN501 targeting Claudin3 protein in various cancers. Approximately 95.3% of its revenue comes from government research contracts.

Number of Employees

34people

Average Salary

72.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

3.04Industry Average 3.824.0Point

In line with industry avg

ROE

-60.24Industry Average -32.113.5Point

1.9x industry avg (good)

Debt Ratio

7.16Industry Average 7.524.0Point

In line with industry avg

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼12.3% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲17.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -173.6% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 80

Positive
에이비온 “ABN202, 전임상 연구서 항암 기전 효과 확인...'AA...
차세대 면역 항암 신약 후보물질 'ABN202'의 전임상 연구에서 TROP2 표적 ADC 대비 월등한 항암 기전 효과를 확인했으며, AACR 2026에서 발표 예정입니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (8%, downtrend)

Current 2,305Won52-week high 6,09152-week low 1,969

1-month return0.0Point

1m -25.65% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral본점소재지변경2026-04-02
Neutral정기주주총회결과2026-03-27
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26
Neutral사업보고서 (2025.12)2026-03-19